By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher this morning reported revenues for its second quarter grew 24 percent year over year, as sales in its Medical Technologies segment grew 31 percent for the period, helped along by its recent purchases of AB Sciex and Molecular Devices.

For the three months ended July 2, revenues grew to $3.31 billion from $2.67 billion in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.